JPRN-jRCT2080222664未知1 期
Clinical Pharmacology study for AS-3201 in hepatic impairment subjects
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •- Subjects who provided written voluntary consent to participate in the study
- •- Child-Pugh class A or B (hepatic impairment subjects)
- •- 45.0 kg < body weight < 80.0 kg and 18.5 < BMI <30.0 kg/m2
排除标准
- •- Subjects who have a serious complication
- •- Subjects who received an AS-3201
研究者
相似试验
已完成
2 期
Phase II study of hepatic arterial infusion of cisplatin for unresectable intrahepatic cholangiocarcinomaintrahepatic cholangiocarcinomaJPRN-UMIN000000809Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East35
已完成
1 期
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic ImpairmentHepatic ImpairmentNCT04293029Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupPharmacokinetics of MDV3100Healthy SubjectsKidney DiseasesNCT01901133Astellas Pharma Europe B.V.33
终止
1 期
A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic ImpairmentInsomniaNCT01257178Eli Lilly and Company
进行中（未招募）
1 期
A Study of LY2157299 in Patients With Liver CancerCarcinoma, hepatocellularMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864EUCTR2010-022338-10-DEEli Lilly and Company204